| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,354 |
18,391 |
$1.05M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
2,501 |
1,859 |
$391K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,037 |
3,746 |
$289K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,462 |
3,157 |
$273K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14,553 |
13,371 |
$170K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
6,802 |
6,308 |
$168K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,893 |
4,672 |
$97K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,205 |
1,102 |
$60K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,472 |
1,342 |
$57K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,195 |
2,756 |
$26K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
1,854 |
1,645 |
$18K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
261 |
253 |
$7K |
| 87807 |
|
106 |
103 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
220 |
204 |
$312.24 |
| 81003 |
|
27 |
26 |
$72.50 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
13 |
13 |
$0.00 |